Loading...
XNAS
INVA
Market cap1.33bUSD
Dec 05, Last price  
20.74USD
1D
-0.29%
1Q
1.27%
Jan 2017
93.83%
IPO
42.64%
Name

Innoviva Inc

Chart & Performance

D1W1MN
XNAS:INVA chart
P/E
57.04
P/S
3.72
EPS
0.36
Div Yield, %
—
Shrs. gr., 5y
-8.14%
Rev. gr., 5y
6.57%
Revenues
359m
+15.54%
12,054,00019,587,00022,002,00023,096,00024,374,00024,223,00024,512,000135,758,0004,758,0008,433,00053,949,000133,569,000217,217,000261,004,000261,016,000336,794,000391,866,000331,339,000310,463,000358,711,000
Net income
23m
-86.98%
-143,164,000-166,044,000-159,997,000-93,643,000-85,302,000-83,862,000-115,344,000-18,542,000-170,701,000-168,464,000-18,760,00059,536,000134,143,000395,056,000157,288,000224,402,000368,837,000213,921,000179,722,00023,392,000
CFO
189m
+33.76%
-58,645,000-104,791,000-104,372,000-99,911,000-58,064,000-75,144,000-88,338,000-127,954,000-129,602,000-130,723,00010,131,00060,984,000141,748,000223,531,000257,458,000313,113,000363,813,000201,726,000141,064,000188,690,000
Dividend
Sep 08, 20150.25 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
URL
https://www.inva.com/
IPO date
Oct 05, 2004
Employees
101
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT